News
Novo Nordisk Names Maziar Mike Doustdar as President and Chief Executive Officer
Effective August 7, 2025, Maziar Mike Doustdar will succeed Lars Fruergaard Jørgensen as Novo Nordisk president and chief executive officer (CEO). Jørgensen will step down from his current role serving as president and CEO on the same day Doustdar is expected to take over.
Pharmaceutical Technology on MSN2d
Novo Nordisk shares plummet as 2025 guidance is cut, overshadowing new CEOCEO-to-be Maziar Mike Doustdar will need to stem the company’s tumbling share price as market pressures intensify.
Professor Lene Oddershede Chief Scientific Officer, Planetary Science & Technology at the Novo Nordisk Foundation talks about the applications of quantum computing at the tech disruptors podcast. She ...
U.S.-listed shares of Novo Nordisk sank in premarket trading Tuesday after the Danish drugmaker cut its full-year outlook and ...
Novo Nordisk has named Maziar Mike Doustdar, currently the company’s EVP of international operations, as the new CEO. Doustdar will succeed Lars Fruergaard Jørgensen, whose surprise abdication was ...
Novo Nordisk (NVO) stock falls as the company names a new CEO and cuts outlook citing pressure on obesity drug sales. Eli ...
Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback